Cargando…

Treatment options for small cell lung cancer – do we have more choice?

Small cell lung cancer (SCLC) is a significant health problem worldwide because of its high propensity for relapse. This review discusses existing and future therapies for the treatment of SCLC.

Detalles Bibliográficos
Autores principales:	Puglisi, M, Dolly, S, Faria, A, Myerson, J S, Popat, S, O'Brien, M E R
Formato:	Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2010
Materias:	Minireview
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2837580/ https://www.ncbi.nlm.nih.gov/pubmed/20104223 http://dx.doi.org/10.1038/sj.bjc.6605527

Ejemplares similares

Cardiovascular assessment in liver transplant for non-alcoholic steatohepatitis patients: What we do, what we should do
por: Sanchez-Torrijos, Yolanda, et al.
Publicado: (2017)

Second-line treatment of advanced hepatocellular carcinoma: Time for more individualized treatment options?
por: Rajappa, Senthil, et al.
Publicado: (2022)

Cancer treatment with kinase inhibitors: what have we learnt from imatinib?
por: Ross, D M, et al.
Publicado: (2004)

What Have We Learned about the Microbiomes of Indoor Environments?
por: Stephens, Brent
Publicado: (2016)

Immunity to SARS-CoV-2: What Do We Know and Should We Be Testing for It?
por: Misra, Anisha, et al.
Publicado: (2022)

Influenza Viruses and mRNA Splicing: Doing More with Less
por: Dubois, Julia, et al.
Publicado: (2014)

Liver transplantation for hepatocellular carcinoma: Where do we stand?
por: Santopaolo, Francesco, et al.
Publicado: (2019)

Nanotherapeutics in transplantation: How do we get to clinical implementation?
por: Plumblee, Leah, et al.
Publicado: (2022)

Advances in surgical management for locally recurrent rectal cancer: How far have we come?
por: Lee, Daniel Jin-Keat, et al.
Publicado: (2017)

The role of multispecies social interactions in shaping Pseudomonas aeruginosa pathogenicity in the cystic fibrosis lung
por: O'Brien, Siobhán, et al.
Publicado: (2017)

Defining the Pseudomonas Genus: Where Do We Draw the Line with Azotobacter?
por: Özen, Asli I., et al.
Publicado: (2011)

Viscoelastic tests in liver disease: where do we stand now?
por: Buliarca, Alina, et al.
Publicado: (2021)

Hepatitis C virus micro-elimination: Where do we stand?
por: Mangia, Alessandra, et al.
Publicado: (2021)

Predicting systemic spread in early colorectal cancer: Can we do better?
por: Brockmoeller, Scarlet Fiona, et al.
Publicado: (2019)

Role of endoscopic ultrasound in liver disease: Where do we stand in 2017?
por: Saraireh, Hamzeh A, et al.
Publicado: (2017)

Expression profiling of small cellular samples in cancer: less is more
por: Glanzer, J G, et al.
Publicado: (2004)

Magnetic resonance enterography in Crohn’s disease: How we do it and common imaging findings
por: Mantarro, Annalisa, et al.
Publicado: (2017)

Image guided percutaneous gastrostomy catheter placement: How we do it safely and efficiently
por: Partovi, Sasan, et al.
Publicado: (2020)

Advanced imaging and artificial intelligence for Barrett's esophagus: What we should and soon will do
por: Spadaccini, Marco, et al.
Publicado: (2022)

Association between acute pancreatitis and COVID-19 infection: What do we know?
por: Jabłońska, Beata, et al.
Publicado: (2021)

Screening and surveillance methods for dysplasia in inflammatory bowel disease patients: Where do we stand?
por: Galanopoulos, Michail, et al.
Publicado: (2018)

Noninvasive markers of liver steatosis and fibrosis after liver transplantation – Where do we stand?
por: Mikolasevic, Ivana, et al.
Publicado: (2021)

Successes and failures: what did we learn from recent first-line treatment immunotherapy trials in non-small cell lung cancer?
por: Remon, Jordi, et al.
Publicado: (2017)

Neuronal characteristics of small-cell lung cancer
por: Onganer, P U, et al.
Publicado: (2005)

Endoscopic therapy for Barrett’s esophagus and early esophageal cancer: Where do we go from here?
por: Singh, Tavankit, et al.
Publicado: (2018)

Gut microbiome dysbiosis in the setting of solid organ transplantation: What we have gleaned from human and animal studies
por: Sharma, Aparna, et al.
Publicado: (2022)

Induction Therapy for Kidney Transplant Recipients: Do We Still Need Anti‐IL2 Receptor Monoclonal Antibodies?
por: Hellemans, R., et al.
Publicado: (2016)

2022 Monkeypox outbreak: Why is it a public health emergency of international concern? What can we do to control it?
por: Ren, Shi-Yan, et al.
Publicado: (2022)

Helicobacter pylori infection and small intestinal bacterial overgrowth–more than what meets the eye
por: Dharan, Murali, et al.
Publicado: (2022)

Angiogenesis inhibitors in clinical development; where are we now and where are we going?
por: Eskens, F A L M
Publicado: (2004)

Migraine pathogenesis and state of pharmacological treatment options
por: Sprenger, Till, et al.
Publicado: (2009)

Raloxifene as a treatment option for viral infections
por: Hong, Subin, et al.
Publicado: (2021)

Progress in immunotherapy for small cell lung cancer
por: Zhao, Dong, et al.
Publicado: (2020)

Outcomes of cesarean scar pregnancy treatment: Do we have options?
por: Yüksel Şimşek, Seda, et al.
Publicado: (2021)

Stereotactic body radiation therapy for non-small cell lung cancer: A review
por: Prezzano, Kavitha M, et al.
Publicado: (2019)

We and herbivores eat endophytes
por: Martínez‐Romero, Esperanza, et al.
Publicado: (2020)

Impact of comorbidities on gout and hyperuricaemia: an update on prevalence and treatment options
por: Bardin, Thomas, et al.
Publicado: (2017)

Overcoming ischemia in the diabetic foot: Minimally invasive treatment options
por: Spiliopoulos, Stavros, et al.
Publicado: (2021)

Post-COVID-19 cholangiopathy: Current understanding and management options
por: Veerankutty, Fadl H, et al.
Publicado: (2023)

Management of early rectal cancer; current surgical options and future direction
por: Chavda, Vijay, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_rjidtl6g4gnrt1hbpcb2dt2l4r